Fennec Pharmaceuticals INC Form 4 insider transactions

Fennec Pharmaceuticals' CFO, Robert Andrade, reported the acquisition of 2,430 common shares through the release of previously restricted stock.

Fennec Pharmaceuticals Director Rosty Raykov acquired 5,208 common shares through the release of restricted stock.

Southpoint Capital Advisors, a 10% owner and director, reported the sale of 19,341 Fennec Pharmaceuticals common shares at a weighted average price of $8.7921 per share.

Southpoint Capital Advisors, a 10% owner and director, reported sales of Fennec Pharmaceuticals common stock totaling 246,018 shares in mid-November 2025.

Fennec Pharmaceuticals Director Rosty Raykov sold 10,000 common shares for $8.10 each, reducing his direct beneficial ownership to 82,318 shares.

Fennec Pharmaceuticals Director Rosty Raykov acquired 5,208 common shares through the release of restricted stock.

Fennec Pharmaceuticals' CFO, Robert Andrade, acquired 2,430 common shares through the release of restricted stock.

Fennec Pharmaceuticals Director Chris Rallis executed pre-planned transactions, exercising stock options and selling a portion of the acquired shares to cover tax obligations.

Southpoint Capital Advisors, a 10% owner and director, reported selling over 67,000 shares of Fennec Pharmaceuticals common stock in early October 2025.

Fennec Pharmaceuticals Director Rosty Raykov has filed to exercise 4,609 stock options on October 8, 2025, acquiring common shares at $2.45 per share.

Fennec Pharmaceuticals Director Rosty Raykov sold 10,000 common shares at $9.78 per share on October 6, 2025, under a pre-arranged 10b5-1 plan.

Fennec Pharmaceuticals Director Rosty Raykov acquired 5,208 common shares through the release of restricted stock, increasing his direct beneficial ownership to 92,501 shares.

Fennec Pharmaceuticals CFO Robert Andrade acquired 2,430 common shares through the release of restricted stock, increasing his direct beneficial ownership to 170,674 shares.

Fennec Pharmaceuticals Director Rosty Raykov acquired 36,207 common shares through the exercise of stock options at a strike price of $2.45.

Fennec Pharmaceuticals Director Rosty Raykov sold 10,000 common shares for $8.92 each, as part of a pre-arranged 10b5-1 trading plan.

Fennec Pharmaceuticals' CFO, Robert Andrade, increased his direct beneficial ownership by 2,431 common shares through the vesting of restricted stock.

Fennec Pharmaceuticals Director Rosty Raykov reported the acquisition of 5,208 common shares through the release of restricted stock.

Fennec Pharmaceuticals Director Rosty Raykov reported the future sale of 10,000 common shares at $8.09 each, executed under a pre-arranged 10b5-1 plan.

Fennec Pharmaceuticals Director Rosty Raykov acquired 5,208 common shares through the release of restricted stock, increasing his beneficial ownership to 65,878 shares.

Fennec Pharmaceuticals Inc.'s Chief Financial Officer, Robert Andrade, acquired 2,431 common shares through the vesting of previously awarded restricted stock.

Fennec Pharmaceuticals Director Chris A. Rallis reported the exercise of 2,127 options at $2.35 per share and the subsequent sale of 1,119 shares at $8.71 to cover tax liabilities, as part of a pre-arranged 10b5-1 plan.

Rosty Raykov, a Director at Fennec Pharmaceuticals Inc., sold 10,000 common shares for $8.61 each, as part of a pre-scheduled 10b5-1 trading plan.

Fennec Pharmaceuticals Inc. Director Rosty Raykov acquired 5,208 common shares through the vesting of previously awarded restricted stock, increasing his total beneficial ownership to 70,670 shares.

Fennec Pharmaceuticals' Chief Financial Officer, Robert Andrade, has acquired 2,431 common shares through the vesting of previously awarded restricted stock, increasing his total beneficial ownership to 163,382 shares.

Rosty Raykov, a Director at Fennec Pharmaceuticals Inc. (FENC), sold 10,000 common shares for $7.78 per share on June 5, 2025, as part of a pre-existing 10b5-1 trading plan.

Fennec Pharmaceuticals Inc. director Jodi Cook was granted 20,000 non-qualified stock options, exercisable at $7.88 per share, pursuant to the company's Equity Incentive Plan.

Fennec Pharmaceuticals Inc. Director Marco Maria Brughera was granted 20,000 non-qualified stock options at an exercise price of $7.88, fully vested on the grant date of June 3, 2025.

Fennec Pharmaceuticals Inc. Director Chris Rallis was granted 20,000 non-qualified stock options, fully vested on the grant date, with an exercise price of $7.88 per share.

Fennec Pharmaceuticals Inc. Director Khalid Islam was granted 25,000 non-qualified stock options at an exercise price of $7.88, fully vested on the grant date of June 3, 2025.

Fennec Pharmaceuticals Inc. Director Rosty Raykov has increased his beneficial ownership of common shares by 5,208 units following the release of restricted stock.